echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Infection > FDA approves emergency use of Comirnaty in children aged 5 to 11 years

    FDA approves emergency use of Comirnaty in children aged 5 to 11 years

    • Last Update: 2021-11-12
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    The FDA this Friday authorized the emergency use of Pfizer and BioNTech's Comirnaty to prevent COVID-19 , including children aged 5 to 11
    .


    The vaccine is given as a two-dose primary series, 21 days apart, but the dose for individuals over 12 is 10 micrograms


    FDA prevents children with COVID-19

    The FDA advisory committee approved the emergency use of Comirnaty in children aged 5 to 11 with a result of 17 votes to 0, meaning that the benefits of Comirnaty outweigh the risks of its use in children aged 5 to 11 years
    .


    The agency pointed out that the US Centers for Disease Control and Prevention (CDC) Immunization Practice Advisory Committee plans to meet next week to discuss further clinical recommendations for the vaccine


    immunity

    The US government has purchased sufficient doses of Comirnaty to vaccinate all children aged 5 to 11 years in the United States, and recently agreed to purchase another 50 million doses of pediatric vaccines for children under 5 years of age
    .

    Pfizer and BioNTech recently reported data from a Phase II/III study, showing that Comirnaty is 90.
    7% effective in preventing symptomatic diseases in children aged 5 to 11
    .


    The results previously announced by the two companies showed that the vaccine was generally well tolerated in the trial and induced a neutralizing antibody response comparable to that of people aged 16 to 25


    Pfizer and BioNTech recently reported data from a Phase II/III study, showing that Comirnaty is 90.


    Peter Marks, director of the FDA's Center for Biologics Evaluation and Research, commented: "We have full confidence in the safety, effectiveness and manufacturing data behind this authorization
    .


    "

     

    Original source:

    Original source:

    https:// href="https://" target="_blank" rel="noopener">https:// https:// Leave a message here

    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.